Vivos Therapeutics Announces Closing of Exercise of Warrants for $4.64 Million Gross Proceeds

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
Seeking Alpha

Vivos Therapeutics’ Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursement

LITTLETON, Colo., April 09, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (VVOS), a leading medical device and technology company specializing in the development and commercialization of highly ...
Seeking Alpha

Vivos Therapeutics Releases Additional Clinical Data Showing Marked Improvement in Pediatric ADHD from Use of Vivos DNA Device

LITTLETON, Colo., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (VVOS), a leading medical device and technology company specializing in the development and commercialization of highly ...

Vivos Inc.

Vivos Inc. company and executive profile by Barron's. View the latest RDGL company infomation and executive bios.
Nasdaq

Vivos Inc. Submitted the Investigational Device Exemption (IDE) Application for Human Clinical Trials at Mayo Clinic

Kennewick, WA, July 14, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a pioneer in Precision Radionuclide TherapyTM (PRnT) solutions, today announced the submission of its Investigational Device ...